ArticleEuropean journal of nuclear medicine and molecular imaging2018
Value of
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06520189 (Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- CanBMJ open · 2021Pooled it
- Preoperative PET/CT phenotype of gastric-type endocervical adenocarcinoma: integrated morphological, metabolic, serological, and explainable machine-learning analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Association between the presence of EGFR or ALK mutations and the location of primary non-small cell lung cancer, as well as metabolic activity observed onOncology letters · 2026Article
- Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer.Translational lung cancer research · 2026Article
- Development and validation of a PET/CT radiomics and dual-task learning model for the prediction of pathological subtypes and EGFR mutation in non-small cell lung cancer.Translational lung cancer research · 2026Article
- Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.Nuklearmedizin. Nuclear medicine · 2026Article
- Ensemble learning strategy-based 18 F-FDG PET/CT metabolic habitats radiomics for predicting EGFR mutation and prognosis in LA-NSCLC: a multi-center study.BMC medical imaging · 2026Article
- An Integrated Clinical-Radiomics-Deep Learning Model Based onCancer medicine · 2025Article
- CT-based radiomics integrated model for brain metastases in stage III/IV ALK-positive lung adenocarcinoma patients.Frontiers in oncology · 2025Article
- ExplainableJournal of cancer research and clinical oncology · 2024Article
- The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA.Heliyon · 2024Article
- The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.BMC pulmonary medicine · 2024Article
- Amide proton transfer-weighted imaging and stretch-exponential model DWI basedCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Machine Learning in Diagnosis and Prognosis of Lung Cancer by PET-CT.Cancer management and research · 2024Review
- Subregion-specificAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Exploring the correlation between HER2 alterations andJournal of cancer research and clinical oncology · 2023Article
- Association between cigarette smoking history, metabolic phenotypes, andJournal of thoracic disease · 2023Article
- Radiogenomics: a key component of precision cancer medicine.British journal of cancer · 2023Review
- Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role ofEJNMMI research · 2023Article
- Retrospective Analysis of the Predictive Value ofDiagnostics (Basel, Switzerland) · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
purposeEpidermal growth factor receptor (EGFR) mutations and the anaplastic lymphoma kinase (ALK) rearrangement are the two most common druggable targets in non-small cell lung cancer (NSCLC). However, genetic testing is sometimes unavailable. Previous studies regarding the predictive role of
methodsWe retrospectively reviewed and included 849 NSCLC patients who were tested for EGFR mutations or ALK status and subjected to
resultsEGFR mutations were identified in 371 patients (45.9%). EGFR mutations were found more frequently in females, non-smokers, adenocarcinomas and stage I disease. Low pSUV
conclusionWe demonstrated that low pSUVmax is associated with mutant EGFR status and could be integrated with other clinical factors to enhance the discriminability on the EGFR mutation status in some NSCLC patients whose EGFR testing is unavailable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.